Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC

Introduction: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regarding the impact of pneumonitis on patient survival. T...

Full description

Bibliographic Details
Main Authors: Yuhei Kinehara, MD, PhD, Takayuki Shiroyama, MD, PhD, Akihiro Tamiya, MD, Motohiro Tamiya, MD, Seigo Minami, MD, PhD, Masaki Kanazu, MD, Osamu Morimura, MD, PhD, Toshie Niki, MD, PhD, Satoshi Tetsumoto, MD, PhD, Yoshihiko Taniguchi, MD, Tomoki Kuge, MD, Kazumi Nishino, MD, PhD, Izumi Nagatomo, MD, PhD, Atsushi Kumanogoh, MD, PhD, Isao Tachibana, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:JTO Clinical and Research Reports
Subjects:
Immune-related adverse event
Chemoradiotherapy
Durvalumab
Pneumonitis
Stage III
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001297

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323001297

Similar Items